Kornimate/medical-research-clean huggingface dataset:
impact of covid-19 on pediatric dental practice during first, second and third wave.

Conditions: SARS-CoV2

Summary: assessment of impact of covid-19 on pediatric dental practice during first, second and third wave among a group of pediatric dentists.

on the 11th of march, 2020, covid-19 (sars-cov-2) was declared as a pandemic by the world health organization. sars-cov-2 is an unpredictable virus that is rapidly transmitting from one country to another, and unfortunately as of today, there is no effective medication or vaccine for the disease control. this virus has gone on to cause one of the most rapidly expanding pandemics with over 9 million people being infected worldwide including the pediatric population. due to the unique nature of dentistry, most dental procedures generate significant amounts of droplets and aerosols, posing potential risks of infection transmission. recent studies have demonstrated the role of the oral mucosa in covid-19 infection, in addition to expressing the ace2 receptor in salivary glands in the asymptomatic process in infected saliva, thus being one of the main sources of viruses. clinical features of covid-19 in children include fever and cough, but a large proportion of infected children appears to be asymptomatic and may contribute significantly to transmission. therefore, it can be assumed that, at this stage in the pandemic, all children and their parents/carers are potentially infective with the potential of cross-infection to dental stuff, parents and the public. this has, in theory, an impact on medical and dental procedures that are aerosol generating procedures.

Eligibility criteria:
inclusion criteria: * egyptian pediatric dentists with at least master's degree. * work place located in egypt. exclusion criteria: * participants who refuse to participate.

Keywords: covid-19 pediatric dentistry
protective effects of propranolol in adults

Conditions: Burn

Summary: this efficacy and safety trial will examine the effects and safety of propranolol administered to adult patients with severe burn injury. the investigators hypothesize that propranolol will provide significant benefit to adults following severe burn injury at doses that are safe and do not increase risk of adverse infectious and non-infectious outcomes.

a safety and efficacy trial is needed in order to determine the safety of propranolol treatment in adult burn patients, identify which subpopulations may be most likely to benefit from propranolol treatment and to identify propranolol dose levels that are not only safe but potentially effective.

Eligibility criteria:
inclusion criteria: * ≥ 20% total body surface area (tbsa) burn with anticipated operation need on admission * age ≥ 18 years * admission within 72 hours of injury exclusion criteria: * age \<18 * patients unlikely to survive injury or with ;age = total burn size ≥ 130 * electrical or deep chemical burn * malignancy currently undergoing treatment or history of cancer treatment within 5 years * history of hiv or aids * presence of anoxic brain injury that is not expected to result in complete recovery * currently treated for chronic obstructive pulmonary disease (copd), asthma or other chronic pulmonary conditions * history of congestive heart failure (chf) (ejection fraction \< 20%) * pre-injury medications including blocking agents (alpha or beta) or other anti-arrhythmic drugs * pregnant women * prisoners * history of cardiac arrhythmia requiring medication * medical condition requiring glucocorticoid treatment * patients with concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
study evaluating bazedoxifene/conjugated estrogens combinations in postmenopausal women

Conditions: Endometrial Hyperplasia; Osteoporosis

Summary: the purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.


Eligibility criteria:
inclusion criteria: * generally healthy, postmenopausal women, aged 40 to less than 65 years * intact uterus * at least 12 months of spontaneous amenorrhea, or 6 months spontaneous amenorrhea with follicle-stimulating hormone (fsh) levels \> 40 miu/ml. exclusion criteria: * use of oral estrogen-, progestin-, androgen-, or serm-containing drug products within 8 weeks before screening (12 weeks for the osteoporosis substudy) * a history or active presence of clinically important medical disease * malabsorption disorders

Keywords: endometrium uterus menopause
to assess the efficacy of the lympha in the prevention of lymphedema following axillary dissection for breast cancer

Conditions: Lymphedema, Breast Cancer

Summary: lymphedema is the build-up of lymph fluid in the body's tissue causing chronic, debilitating swelling. this commonly occurs as a result of a disruption of the lymphatic system during lymph node dissection surgeries. lympha (lymphatic microsurgical preventive healing approach) is an innovative microsurgical technique where blocked lymphatic vessels are drained into the blood circulation by surgically creating a shunt between a lymphatic channel and a blood vessel called a lymphatic-venous bypass. recently, lympha technique has been shown to prevent lymphedema when performed at the time of nodal dissection. we propose a prospective study evaluating the effectiveness of lympha technique using objective clinical protocol.

consenting patients will have the lympha procedure at the time of planned axillary dissection surgery for the prevention of upper and extremity lymphedema. the node dissection will be performed by dr. kang while the lympha technique will be performed by the plastic surgeon, dr. kim. the lympha procedure consist of performing lva at the time of the node dissection. patent blue dye will be injected in the volar surface of the upper third of the arm in a quantity of about 1-2 ml intradermally, subcutaneously, and under muscular fascia into patient approximately 10 minutes before skin incision. this will allow mapping of the lymphatic channels for identification for bypass. the node dissection will then be performed with preservation of the anterior branch of the axillary vein in the axilla. afferent lymphatic vessels will be sutured into a branch of the axillary vein distal to a competen valve. the total duration of the surgery is approximately 3 hours. the lympha technique accounts for an additional 30 min to the standard 2-2.5 hours allocated to the node dissection. pre-surgery, patients will have baseline limb circumference measurements of both the surgery-affected and unaffected arms and by lymphoscintigraphy. patients will be followed up clinically at every 6 months up to a year. at each follow-up visit, patients will have a physical examination and their circumference of their limbs taken. patients will also fill out a lyqli, sf-36, dash administered by the clinical research coordinator pre-and post-surgery. each patient will have a total of 1 years of participation time.

Eligibility criteria:
inclusion criteria: * node-positive cancer requiring an axillary or lymphadenectomy * below 30 body mass index exclusion criteria: * patients receiving a sentinel lymph node biopsy * patients with established preoperative lymphedema * patients with post-thrombotic syndrome, peripheral vascular disease * pregnant patients
making decisions about participating in a cancer clinical trial for patients with stage ii, stage iii, or stage iv pancreatic cancer or stage iii or stage iv colon cancer or rectal cancer

Conditions: Colorectal Cancer; Pancreatic Cancer; Psychosocial Effects of Cancer and Its Treatment

Summary: rationale: determining how patients makes decisions about participating in a clinical trial may help doctors plan clinical trials in which more patients are willing to participate and are satisfied with their decision to participate. purpose: this clinical trial is studying how patients with stage ii, stage iii, or stage iv pancreatic cancer or stage iii or stage iv colon cancer or rectal cancer make decisions about participating in a clinical trial.

objectives: * determine the relationship between disease factors, patient factors, and understanding of the cancer clinical trial, and preferences for decision control in the decision to participate in a cancer clinical trial by patients with stage ii-iv pancreatic cancer or stage iii-iv colon or rectal cancer. * determine the relationship between disease factors, patient factors, understanding of the cancer clinical trial, and preferences for decision control with satisfaction with the decision to participate in a cancer clinical trial. * determine how quality of life, trust, and hope impact the decision to participate in a cancer clinical trial and the satisfaction with this decision. outline: this is a cross-sectional study. patients complete 12 questionnaires to assess their symptom burden (e.g., nausea, pain, fatigue), sociodemographics, hope, quality of life, trust in the healthcare system, trust in health professionals, research decision control, perceived risks, adequacy of research information, clinical trial participation, and decision satisfaction. projected accrual: a total of 200 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of 1 of the following: * stage ii-iv pancreatic cancer * stage iii-iv colon cancer * stage iii-iv rectal cancer * offered the opportunity to participate in a phase i-iii cancer clinical trial and agreed or declined to participate * first appointment at the sidney kimmel comprehensive cancer center at john hopkins patient characteristics: * able to read english prior concurrent therapy: * not specified

Keywords: psychosocial effects of cancer and its treatment stage iii colon cancer stage iv colon cancer stage iii rectal cancer stage iv rectal cancer stage ii pancreatic cancer stage iii pancreatic cancer stage iv pancreatic cancer
precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing

Conditions: Liver Cancer; Liver Metastasis Colon Cancer

Summary: this will be a prospective, observational, cohort study to determine the impact of integrated diagnostics using quantitative magnetic resonance imaging, whole genome sequencing and digital pathology on intended patient management for liver cancer patients referred for liver resection. participants with primary or secondary liver cancer will be recruited from hampshire hospitals nhs foundation trust in basingstoke or oxford university hospitals nhsfoundation trust in oxford. the incidence of treatable liver tumours is on the rise globally, driven by obesity, viral hepatitis and metastases from colorectal cancers. survival rates can be improved with optimised allocation of treatment options including surgical resection, radiofrequency ablation, embolisation, chemotherapy and targeted molecular therapies (including immunotherapy). the key motivation of this study is to help patients access the most suitable treatment combinations, based on integrating clinical, radiological and genomic data. a similar integrated approach, integrating radiology and pathology, has been shown to improve outcomes in breast cancer care. detailed pathologic analysis of the surgical specimen from breast carcinoma biopsy provides valuable feedback to the radiologist, establishes the completeness of surgical intervention, and generates predictive information for therapeutic decisions. whole genome sequencing (wgs) has discovered cancer driver mutations and the complex molecular profile of liver cancer. in many metastatic solid tumours, wgs has been used to identify a significant patient population (31%) who present with a biomarker that predicts sensitivity to a drug and lacked any known resistance biomarkers for the same drug. identifying which patients possess druggable mutations will allow clinicians to make the optimal treatment decisions. the next challenge is integrating wgs into scalable clinical practice


Eligibility criteria:
inclusion criteria: * male or female 18 years of age and older willing and able to give informed consent to participate in the study * patients being considered for liver resection for primary or secondary liver cancer. exclusion criteria: * the participant may not enter the study with any known contraindication to magnetic resonance imaging (including but not limited to pregnancy, a pacemaker or other metallic unfixed implanted device, metallic fragments, extensive tattoos, severe claustrophobia). * any other cause, including a significant underlying disease or disorder which, in the opinion of the investigator, may put the participant at risk by participating in the study or limit the participant's ability to participate.

Keywords: mri surgery whole genome sequencing
effect of selenium supplementation on glycemic control in patients with type 2 diabetes or prediabetes

Conditions: Type 2 Diabetes; PreDiabetes

Summary: although it has been suggested that selenium (se) increases the risk of t2dm, most evidence comes from observational studies that cannot prove causality. a systematic review assessed randomized clinical trials and found that the risk of t2dm was not greater in those randomized to se supplementation than in those randomized to placebo. se is a toxic element in animals and humans, and overexposure to se has also been linked to detrimental health effects in humans. previous studies were mostly conducted in se-sufficient areas. moreover, the effectiveness of low-dose se supplementation on participants with elevated glycemic status was unknown. this cross-over, double blinded, randomized controlled trail aimed to investigate the effectiveness of se supplementation for glucose control among participants with diabetes or prediabetes. moreover, we also aimed to examine whether selenoprotein p genotypes, se-related gut microbiota and their related metabolite modified the effectiveness.


Eligibility criteria:
inclusion criteria: 1. fpg ≥ 5.6 mmol/l; 2. hba1c ≥ 5.7%; 3. ogtt 2h or postprandial blood glucose ≥ 7.8 mmol/l. 4. t2d patients with stable anti-diabetic medication and blood glucose controlled well for 4 weeks prior. exclusion criteria: 1. under 30 years old or above 70 years old; 2. pregnancy; 3. major surgery in the previous 6 months or planned to occur during the trail; 4. insulin injection for diabetes; 5. suffering from severe obesity (bmi \> 40 kg/m2), immunodeficiency syndrome, thyroid disease, coronary heart disease, stroke, malignant neoplasm, kidney or liver disease, or other serious diseases, such as mental illness; 6. reduced kidney function (gfr \ 1.2 times the normal upper limit \[male, \> 133.2 μmol/l; female \> 100 μmol/l\]); 7. systolic or diastolic blood pressure greater than 160 or 100 mmhg; 8. taking dietary supplements (e.g., selenium, vitamin, fish oil, etc.) for nearly one month before the intervention; 9. taking antibiotics or probiotics within 12 weeks of screening.

Keywords: selenium type 2 diabetes prediabetes
long-term prevention of recurrent gastric or duodenal ulcers caused by low-dose aspirin with rabeprazole (e3810) treatment (planetarium study)

Conditions: Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin

Summary: the primary objective of this study to examine the long-term safety of rabeprazole 5 mg or 10 mg tablets administered once daily in participants who were confirmed to have no recurrence of gastric or duodenal ulcer by endoscopic examination at the end of 24 weeks of treatment in the e3810-j081-308 (nci01397448) \[double-blind phase\] study. from a total of 420 participants who completed the e3810-j081-308 study, 328 entered the e3810-j081-309 (nct01398410) study.

the e3810-j081-309 consisted of two arms: the long-term rabeprazole groups (participants from the rabeprazole 5 or 10 mg arm of the e3810-j081-308 study who entered the rabeprazole 5 mg or 10 mg arm of the e3810-j081-309 study) and the newly-initiated rabeprazole groups (participants from the teprenone 150 mg arm of the e3810-j081-308 study who entered the rabeprazole 5 mg or 10 mg arm of the e3810-j081-309 study).

Eligibility criteria:
inclusion criteria * confirmed to have no recurrence of gastric or duodenal ulcer by endoscopy at the end of 24 weeks of treatment in study e3810-j081-308. * need to continue receiving low-dose aspirin (81 mg/day or 100 mg/day) during this study. exclusion criteria -confirmed to have a recurrence of gastric or duodenal ulcer at the end of 24 weeks of treatment in study e3810-j081-308 (at the start of this trial) and thus are withdrawn from the trial.

Keywords: rabeprazole proton pump inhibitor acetylsalicylic acid aspirin gastric ulcer duodenal ulcer
an multicentre clinical study to evaluate the usability and safety of the pre-filled pen and pre-filled syringe of sb5 in subjects with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: a study comparing the use of the pre-filled pen and pre-filled syringe of sb5 in subjects with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: 1. are male or female aged 18-55 years at the time of signing the informed consent form. 2. have been diagnosed as having ra according to the revised 1987 american college of rheumatology (acr) criteria for at least 6 months prior to screening. 3. subjects who are considered by the investigator to be a suitable candidate for self-administering adalimumab treatment 4. must be able to provide informed consent, which must be obtained prior to any study related procedures. exclusion criteria: 1. have been treated previously with any biologic agents including any tumour necrosis factor inhibitor. 2. have a known hypersensitivity to human immunoglobulin proteins or other components of sb5. 3. have a current diagnosis of active tuberculosis (tb), have been recently exposed to a person with active tb, or are considered to have latent tb indicated by a positive quantiferon® gold test result. 4. have had a serious infection (such as sepsis, abscess, opportunistic infections or invasive fungal infection including histoplasmosis) or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to first dose of ip. nonsignificant infections do not need to be considered exclusionary at the discretion of the investigator. 5. have a history of chronic or recurrent infection (such as chronic renal infection, chronic chest infection or recurrent urinary infection). 6. have any of the following conditions: 1. history of congestive heart failure (new york heart association class iii/iv) 2. history of demyelinating disorders (such as multiple sclerosis or guillain-barré syndrome). 3. history of any malignancy (other than lymphoproliferative disease and melanoma, see exclusion criteria 10.f) within the previous 5 years prior to screening except completely excised and cured squamous carcinoma of the uterine cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma. 4. history of lymphoproliferative disease including lymphoma or melanoma. 5. any other disease or disorder which, in the opinion of the investigator, will put the subject at risk if they are enrolled.
the effect of rectal and sublingual misoprostol administration in postpartum or intrapartum haemorrhage at elective caesarean delivery: a randomized controlled trial

Conditions: ıntrapartum Haemorrhage; Postpartum Haemorrhage

Summary: the investigators hypothesis in this study is that administration of rectal and sublingual misoprostol decreases intrapartum and postpartum haemorrhage.


Eligibility criteria:
inclusion criteria: 1. live and singleton pregnancy 2. elective caesarean 3. gestational week greater than 37 weeks 4. patient between 18-44 year old exclusion criteria: 1. -multiple pregnancy 2. preeclampsia 3. gestational diabetes 4. macrosomia 5. oligohidraamnıos 6. polihidraamnıos 7. myoma 8. morbid obesity 9. coagulatıon defect (such as hellp syndrome)
the effect of chronic stress on efficacy of icis in esophageal cancer patients (stress-esca study)

Conditions: Esophageal Cancer; Immunotherapy

Summary: chronic stress refers to a special emotional state caused by unexpected stress for a long time, with an increasing incidence in the population. it can cause the body to release hormones such as cortisol and adrenaline. tumor patients often experience changes such as psychological and emotional abnormalities, decreased quality of life, and impaired social relationships. under stimulation, patients often experience negative reactions such as anxiety or depression. epidemiological studies have shown that stress can affect the prognosis of malignant tumors, but the effect of stress on the efficacy and prognosis of esophageal cancer is still unclear. in animal models, chronic stress leads to an increase in tissue catecholamine levels, increased tumor burden, and increased invasiveness of ovarian cancer cells in mouse models. at the same time, stress can promote tumor neovascularization in mice. however, the mechanism by which chronic stress affects the occurrence and development of esophageal cancer is currently unclear. in addition to neurohumoral factors, chronic stress can cause changes in the gut microbiota, which in turn affects the body's digestion, metabolism, and immune function. it is a key gatekeeper of the immune response to tumors. therefore, gut microbiota as an intermediate factor may also affect the occurrence and prognosis of various types of esophageal cancer.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years and ≤ 75 years old 2. pathologically diagnosed as esophageal cancer 3. patient tumor tissue samples can be obtained 4. at least one measurable lesion can be evaluated according to the recist 1.1 standard 5. as a newly treated patient, they have not received systematic anti-tumor treatment for locally advanced or metastatic chest tumors 6. there is no obvious abnormality in the electrocardiogram and no obvious cardiac dysfunction 7. hematology and liver and kidney function indicators meet the requirements exclusion criteria: 1. merge with other malignant tumors 2. long term use of hormones or immunosuppressants 3. concomitant acute or chronic mental illness 4. patients who have been taking drugs that can alter the activity of the sympathetic nervous system for a long time or are currently taking them 5. other malignant diseases that require systematic treatment 6. patients who have undergone other clinical drug experiments before 7. patients with symptomatic brain metastases